Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?

被引：5
|
作者：
Pritchard, Kathleen I. [1 ]
机构：
[1] Sunnybrook Odette Canc Ctr, Toronto, ON M4N 3M5, Canada
来源：
BREAST CANCER RESEARCH | 2010年 / 12卷
关键词：
Tamoxifen; Fluoxetine; Sertraline; Venlafaxine; Fluvoxamine;
D O I：
10.1186/bcr2747
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 43 条
  • [21] Metabolic bone abnormalities and fracture risk in women with estrogen receptor positive breast cancer switching from tamoxifen to an aromatase inhibitor: Concerns about individual bone health management issues.
    Clunie, G. P. R.
    Mortimer, C. J. D.
    Archer, T. J.
    Sherwin, K. E.
    Clark, A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S347 - S347
  • [22] Administration of LHRH agonist as an adjuvant endocrine therapy for breast cancer is a risk factor of ovarian function recovery after switching from tamoxifen to aromatase inhibitor
    Ishige, H.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S55 - S55
  • [23] Tissue Inhibitor of Metalloproteinases-1 status measured by immunohistochemistry in 242 estrogen receptor positive postmenopausal high-risk breast cancer patients treated with adjuvant tamoxifen
    Bjerre, C.
    Knoop, A.
    Lyng, M.
    Ditzel, H.
    Bartels, A.
    Brunner, N.
    Laenkholm, A. V.
    APMIS, 2010, 118 : 16 - 16
  • [24] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective
    Delea, TE
    Karnon, J
    Thomas, SK
    Barghout, V
    Papo, NL
    Johnston, SRD
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S102 - S102
  • [25] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    Delea, Thomas E.
    El-Ouagari, Khalid
    Karnon, Jonathan
    Sofrygin, Oleg
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (03) : 375 - 387
  • [26] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    Thomas E. Delea
    Khalid El-Ouagari
    Jonathan Karnon
    Oleg Sofrygin
    Breast Cancer Research and Treatment, 2008, 108 : 375 - 387
  • [27] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a Canadian perspective
    Delea, Thomas E.
    El Ouagari, Khalid
    Karnon, Jon
    Sofrygin, Oleg
    Barghout, Victoria
    ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
  • [28] Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort
    Danja Sarink
    Helena Schock
    Theron Johnson
    Jenny Chang-Claude
    Kim Overvad
    Anja Olsen
    Anne Tjønneland
    Patrick Arveux
    Agnès Fournier
    Marina Kvaskoff
    Heiner Boeing
    Anna Karakatsani
    Antonia Trichopoulou
    Carlo La Vecchia
    Giovanna Masala
    Claudia Agnoli
    Salvatore Panico
    Rosario Tumino
    Carlotta Sacerdote
    Carla H. van Gils
    Petra H. M. Peeters
    Elisabete Weiderpass
    Antonio Agudo
    Miguel Rodríguez-Barranco
    José María Huerta
    Eva Ardanaz
    Leire Gil
    Kay Tee Kaw
    Julie A. Schmidt
    Laure Dossus
    Mathilde His
    Dagfinn Aune
    Elio Riboli
    Rudolf Kaaks
    Renée T. Fortner
    BMC Cancer, 18
  • [29] Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort
    Sarink, Danja
    Schock, Helena
    Johnson, Theron
    Chang-Claude, Jenny
    Overvad, Kim
    Olsen, Anja
    Tjonneland, Anne
    Arveux, Patrick
    Fournier, Agnes
    Kvaskoff, Marina
    Boeing, Heiner
    Karakatsani, Anna
    Trichopoulou, Antonia
    La Vecchia, Carlo
    Masala, Giovanna
    Agnoli, Claudia
    Panico, Salvatore
    Tumino, Rosario
    Sacerdote, Carlotta
    van Gils, Carla H.
    Peeters, Petra H. M.
    Weiderpass, Elisabete
    Agudo, Antonio
    Rodriguez-Barranco, Miguel
    Maria Huerta, Jose
    Ardanaz, Eva
    Gil, Leire
    Kaw, Kay Tee
    Schmidt, Julie A.
    Dossus, Laure
    His, Mathilde
    Aune, Dagfinn
    Riboli, Elio
    Kaaks, Rudolf
    Fortner, Renee T.
    BMC CANCER, 2018, 18
  • [30] Receptor for advanced glycation end-product rs1800624 polymorphism contributes to increase breast cancer risk Evidence from a meta-analysis
    Zhang, Wei
    Deng, Xiaowei
    Tang, Ruijun
    Wang, Hong
    MEDICINE, 2020, 99 (44) : E22775
12345